What time is the conference call scheduled for?

The conference call will take place at 8:00 a.m. ET.

How can investors access the live conference call?

Investors can access the live call by dialing 833-470-1428 for domestic calls or 404-975-4839 for international calls, using conference ID 387547.

How long will the archived webcast of the conference call be available?

The archived webcast will be available approximately two hours after the call and will remain accessible for 30 days.

What are the core focus areas of Blueprint Medicines Corporation?

Blueprint Medicines focuses on developing medicines for allergy/inflammation and oncology/hematology, with a goal of addressing significant medical issues.

Blueprint Medicines to Report Third Quarter 2024 Financial Results on Wednesday, October 30, 2024

Q: When will Blueprint Medicines Corporation report its third quarter 2024 financial results?

Blueprint Medicines Corporation will report its third quarter 2024 financial results and provide a corporate update on October 30, 2024.

10/16/24 8:00:00 AM ET

$BPMC

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $BPMC alert in real time by email

CAMBRIDGE, Mass., Oct. 16, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Wednesday, October 30, 2024, to report its third quarter 2024 financial results and provide a corporate update.

To access the live conference call, please dial 833-470-1428 (domestic) or 404-975-4839 (international) and refer to conference ID 387547. A webcast of the call will also be available under "Events and Presentations" in the Investors & Media section of the Blueprint Medicines website at http://ir.blueprintmedicines.com/. The archived webcast will be available on Blueprint Medicines' website approximately two hours after the conference call and will be available for 30 days following the call.

About Blueprint Medicines

Blueprint Medicines is a global, fully integrated biopharmaceutical company that invents life-changing medicines. We seek to alleviate human suffering by solving important medical problems in two core focus areas: allergy/inflammation and oncology/hematology. Our approach begins by targeting the root causes of disease, using deep scientific knowledge in our core focus areas and drug discovery expertise across multiple therapeutic modalities. We have a track record of success with two approved medicines, including AYVAKIT®/AYVAKYT® (avapritinib) which we are bringing to patients with systemic mastocytosis (SM) in the U.S. and Europe. Leveraging our established research, development, and commercial capability and infrastructure, we now aim to significantly scale our impact by advancing a broad pipeline of programs ranging from early science to advanced clinical trials in mast cell diseases including SM and chronic urticaria, breast cancer and other solid tumors. For more information, visit www.BlueprintMedicines.com and follow us on X (formerly Twitter; @BlueprintMeds) and LinkedIn.

View original content to download multimedia:https://www.prnewswire.com/news-releases/blueprint-medicines-to-report-third-quarter-2024-financial-results-on-wednesday-october-30-2024-302275822.html

SOURCE Blueprint Medicines Corporation

Get the next $BPMC alert in real time by email

Recent Analyst Ratings for

$BPMC

Date	Price Target	Rating	Analyst
11/14/2024	$126.00	Overweight	JP Morgan
10/24/2024	$88.00	Neutral	UBS
5/14/2024	$140.00	Overweight	Stephens
5/6/2024	$50.00 → $97.00	Underperform → Market Perform	Leerink Partners
10/27/2023	$85.00	Perform → Outperform	Oppenheimer
8/21/2023	$65.00 → $66.00	Buy	Needham
7/31/2023	$55.00 → $82.00	Equal Weight → Overweight	Wells Fargo
6/5/2023	$48.00 → $43.00	Market Perform → Underperform	SVB Securities

More analyst ratings

Blueprint Medicines to Report Third Quarter 2024 Financial Results on Wednesday, October 30, 2024

Chat with this insight

Q&A

When will Blueprint Medicines Corporation report its third quarter 2024 financial results?

What time is the conference call scheduled for?

How can investors access the live conference call?

How long will the archived webcast of the conference call be available?

What are the core focus areas of Blueprint Medicines Corporation?

Recent Analyst Ratings for $BPMC

$BPMC SEC Filings

SEC Form 10-Q filed by Blueprint Medicines Corporation

Blueprint Medicines Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form 10-Q filed by Blueprint Medicines Corporation

$BPMC Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Albers Jeffrey W. exercised 5,000 shares at a strike of $36.05 and sold $510,000 worth of shares (5,000 units at $102.00) (SEC Form 4)

PRESIDENT, R & D Namouni Fouad sold $324,500 worth of shares (3,633 units at $89.32), decreasing direct ownership by 5% to 69,070 units (SEC Form 4)

Director Albers Jeffrey W. exercised 10,000 shares at a strike of $36.05 and sold $1,685,891 worth of shares (19,702 units at $85.57), decreasing direct ownership by 6% to 157,557 units (SEC Form 4)

$BPMC Market Insights

Live Market Insights

Morgan Stanley Maintains Equal-Weight on Blueprint Medicines, Raises Price Target to $115

Oppenheimer Maintains Outperform on Blueprint Medicines, Raises Price Target to $125

Expert Ratings For Blueprint Medicines

$BPMC Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Blueprint Medicines Corporation

SEC Form SC 13G/A filed by Blueprint Medicines Corporation (Amendment)

SEC Form SC 13G/A filed by Blueprint Medicines Corporation (Amendment)

$BPMC Leadership Updates

Live Leadership Updates

Blueprint Medicines Submits Supplemental New Drug Application to FDA for AYVAKIT® (avapritinib) for the Treatment of Indolent Systemic Mastocytosis

Guardant Health and Blueprint Medicines present real-world data identifying EGFR C797X mutation as most common resistance mechanism to osimertinib therapy at IASLC 2022 World Conference on Lung Cancer

Blueprint Medicines Publishes Inaugural Corporate Responsibility Report

$BPMC Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

JP Morgan initiated coverage on Blueprint Medicines with a new price target

UBS initiated coverage on Blueprint Medicines with a new price target

Stephens initiated coverage on Blueprint Medicines with a new price target

$BPMC Financials

Live finance-specific insights

Blueprint Medicines Reports Third Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance